Drug Trial Radar · NCT07429838
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Dec 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- eGenesis, INCIndustry
- Sponsor type
- Industry
- Collaborators
- OrganOx Ltd.
- First posted
- Feb 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants with Grade 2 to Grade 3 acute-on-chronic liver failure (ACLF) and hepatic encephalopathy Grade 1-3. The metra® device has been modified for the purposes of cross-circulation with an extra-corporeal porcine liver. The EGEN-5784 liver and metra® ELC system are designed to support liver function during the treatment period
Conditions
- Acute on Chronic Liver Failure (ACLF)
- Hepatic Encephalopathy (HE)
Interventions
metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx)Device
Perfusion circuit/device enabling extracorporeal cross-circulation between the participant and the EGEN-5784 porcine liver. Planned support up to 72 h in Part 1 and up to 120 h in Part 2 if no safety/stopping criteria are met, with ICU-level monitoring and protocol-defined operating parameters.
EGEN-5784 (genetically engineered porcine liver)Biological
Viable porcine liver from a genetically engineered donor (EGEN-5784) used for temporary extracorporeal cross-circulation support. The liver is not implanted; it is perfused in a closed circuit with the participant under continuous monitoring and predefined stopping rules per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of TESAE'sTime frame: From ELC initiation to 28 days post-ELC initiation
- Incidence of AESIsTime frame: From ELC initiation through 28 days post ELC initation
- Incidence of Device DeficienciesTime frame: From metra® initiation through metra® ELC termination (assessed continuously during the ELC procedure; up to 72 hours in Part 1 and 120 hours in Part 2)
- Incidence of UADEsTime frame: From metra® initiation through metra® ELC termination (assessed continuously during the ELC procedure; up to 72 hours in Part 1 and 120 hours in Part 2)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Washington University
St Louis, Missouri
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.